Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1253 - Efficacy of amrubicin monotherapy after platinum chemotherapy for non-gastrointestinal extrapulmonary neuroendocrine carcinoma


08 Oct 2016


Poster Display


Takahiro Ebata


Annals of Oncology (2016) 27 (6): 136-148. 10.1093/annonc/mdw369


T. Ebata1, T. Shimoi2, S. Bun3, M. Yunokawa4, K. Yonemori4, T. Ishiwata1, S. Iwasawa1, K. Tamura4, Y. Takiguchi1

Author affiliations

  • 1 Medical Oncology, Chiba University, School of Medicine, 2608677 - Chiba/JP
  • 2 Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3 Pharmacy, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 4 Breast And Medical Oncology, National Cancer Center Hospital, 1040045 - Tokyo/JP


Abstract 1253


NEC rarely arises in extra-pulmonary sites. Although chemotherapeutic regimens for small cell lung cancer (SCLC) are empirically administrated for unresectable extra-pulmonary NEC in the first-line setting, the 2nd line treatment is not established because of its rarity. Amrubicin has clinical relevance for platinum-refractory SCLC and gastrointestinal NEC. However, there is no data for non-gastrointestional extra-plumonary NEC.


In this retrospective study of two hospitals, eligible patients 1) had a definitive diagnosis of non-gastrointestinal extra-pulmonary NEC, 2) were refractory to platinum-based chemo, and 3) were treated between January 2008 and December 2014 with 4) amrubicin monotherapy at a dose of 40mg/m2 on days 1 to 3 every 3 weeks. The platinum-free interval was defined as the duration from the last day of platinum administration to the first progression.


Fourteen eligible patients including 6 men (42.9%) were extracted with the median age of 62 years (range 43-86). Primary sites included genitourinary organs in 5, gynecological organs in 2, thymus in 2 and others. Results included ORR of 40%, median PFS and OS of 181 and 319 days respectively. Platinum-free interval over 90 days was a significant factor for favarable PFS (p = 0.0022). Grade 3/4 adverse events were neutropenia (80%) and febrile neutropenia (30%). Treatment related death was observed in one with febrile neutropenia.


Amrubicin showed modest efficacy for patients with platinum-refractory non-gastrointestinal extra-pulmonary NEC with modestly frequent adverse events.

Clinical trial identification

Legal entity responsible for the study

Chiba University




Y. Takiguchi: I received lecture fee by Nipponkayaku.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings